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Heterotopic hamster hearts transplanted to unmodi-
fied LEW rats underwent humoral rejection in 3 days. 
Survival was prolonged to a median of 4 days with 2 
mg/kg/day FK506. As monotherapy, 15 mg/kg/day cy-
clophosphamide greatly prolonged graft survival-far 
more than could be accomplished with RS-61443, bre-
quinar (BQR), mizoribine, methotrexate, or deoxysper-
gualin. However, when FK506 treatment, which was 
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ineffective alone, was combined with a short induction 
course (14 or 30 days) of subtherapeutic BQR, RS-
61443, or cyclophosphamide, routine survival of heart 
xenografts was possible for as long as the daily FK506 
was continued. In addition, a single large dose of 80 mg/ 
kg cyclophosphamide 10 days preoperatively allowed 
routine cardiac xenograft survival under FK506. The 
ability of these antimetabolites to unmask the therapeu-
tic potential of FK506 correlated, although imperfectly, 
with the prevention of rises of preformed heterospecific 
cytotoxic antibodies immediately postoperatively. As an 
adjunct to FK506, azathioprine was of marginal value, 
whereas mizoribine, methotrexate, and deoxyspergu-
aHn (DSPG) were of intermediate efficacy. 
After orthotopic hepatic xenotransplantation, the per-
ioperative surviva.l of the liver with its well-known 
-------_._--
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resistance to antibodies was less dependent than the 
heart on the antimetabolite component of the combined 
drug therapy, but the unsatisfactory results with mon-
otherapy of FK506, BQR, RS-61443, or cyclophospha-
mide were changed to routine success by combining 
continuous FK506 with a short course of any of the 
other drugs. Thus, by breaking down the antibody bar-
rier to xenotransplantation with these so-called antipro-
liferative drugs, it has been possible with FK506 to 
transplant heart and liver xenografts with consistent 
long-term survival of healthy recipients. 
FK506, which prevents T cell activation and cytokine secre-
tion by inhibiting the transcription of early genes (1), has 
permitted improvements in the clinical transplantation of a 
variety of allografts (2, 3). However, the drug has a minimal 
effect on B cells and the antibody response, and does not 
prevent humoral allograft rejection in the presensitized recipi-
ent (4, 5) or the rejection of xenografts by heterospecific 
antibodies (6, 7). 
In a hamster-to-rat xenograft model, we have combined 
FK506 with drugs that subvert the action of key enzymes of de 
novo purine and pyrimidine nucleotide synthesis, thereby in-
hibiting the DNA synthesis required for expansion of activated 
T and/or B cell clones. Brequinar (BQR),* an agent the im-
munosuppressive qualities of which were studied in rats by 
Cramer et a1. (8) and RS-61443, a mycophenolic acid derivative 
showing considerable preclinical and clinical promise (9-12), 
where the new prototype drugs selected. However toward the 
end of the study, established anti-DNA drugs also were evalu-
ated as adjuvants, including azathioprine, cyclophosphamide, 
and methotrexate; of these cyclophosphamide, was found to be 
spectacularly effective. Finally, FK506 was combined with 
deoxyspergualin (DSPG), a putative antimacrophage/mono-
cyte drug that also has been said to suppress B cell activation 
and maturation (13). 
MATERIALS AND METHODS 
Animals. Inbred male Lewis rats (LEW, RT11) weighing 200-300 g 
were recipients, and Golden Syrian hamsters weighing 100-150 g were 
donors (Charles River Lab., Wilmington, MA). 
Surgical procedure. The hamster-to-rat xenograft models were those 
characterized previously by Valdivia and Monden (14-17). Operations 
were under methoxyflurane anesthesia. Heterotopic heart transplan-
tation was performed by anastomosing the donor aorta and pulmonary 
artery of the xenograft to the recipient infrarenal abdominal aorta and 
vena cava, respectively. The cardiac grafts were palpated daily for the 
first month and every other day thereafter. Rejection was diagnosed by 
the cessation of the heartbeat, and confirmed by direct inspection at 
reoperation and by histopathology. There was no discard rate of failed 
experiments. 
Liver transplantation after graft cholecystectomy was performed 
with Kamada's cuff technique for the portal and infrahepatic vena cava 
anastomoses, revascularizing the portal vein only (14-17). Rejection 
was diagnosed by the death of the recipients, followed by histopatho-
logical examination. Animals dying <3 days after surgery were excluded 
from the study (less than 5% of the total). This small rate of discard 
was from technical misadventures. 
Immunosuppressive agents. FK506: FK506 ( a gift of the Fujisawa 
Pharmaceutical Co., Osaka, Japan) was given i.m. after suspending it 
in normal saline. The dose for heart recipients was 2.0 mg/kg/day on 
days 0 to 5 followed by 1.0 mg/kg/day on days 6 to 30. For liver 
xenotransplantation, 1.0 mg/kg/day was used for the first 30 days. 
• Abbreviations: BQR, brequinar; DSPG, deoxyspergualin. 
Both liver and heart recipients were given alternate-day injections of 
0.5 mg/kg FK506 from days 31 to 100. 
Antiproliferative drugs: All of these drugs were prepared daily and 
administered by gastric instillation. BQR (donated by Du Pont Medical 
Products, Wilmington, DE) was suspended in distilled water, and 
adjusted with NaOH to pH 9.0. RS-61443 (donated by Syntex Inc, Palo 
Alto, CAl was used in a special vehicle that contained 0.5% carboxy-
methyl-cellulose, 0.4% polysorbate 80, 0.9% benzyl alcohol, and 0.9% 
sodium chloride in distilled water. Mizoribine (Bredinin, donated by 
Asahi Chemical Industry Co. Ltd., Tokyo, Japan) was suspended in 
distilled water. Azathioprine, cyclophosphamide, and methotrexate 
were bought from commercial pharmacies and suspended in distilled 
water. 
Deoxyspergualine: This gift from Nippon Kayaku Co. Ltd, Tokyo, 
(later Bristol-Myers Squibb) was suspended in sterile water and ad-
ministered intramuscularly. 
Recipient humoral antibodies. Lymphocytotoxic antibodies: Comple-
ment-fixing Iymphocytotoxic antibodies were measured in the recipient 
rat sera by Terasaki's method (18), using target lymphocytes prepared 
from hamster cervical lymph nodes. After washing and isolation, the 
cells were resuspended at a concentration of 4x106/ml. Duplicate 
samples of 1 III of various dilutions of serum samples and one III of 
lymphocyte suspensions were placed into 72-well tissue-typing trays 
(Robbins Scientific, Sunnyvale, CAl. After incubation for 60 min at 
room temperature, 5 III of baby rabbit complement diluted 10 times 
(Cedarlane Laboratories Limited, Hornby, Ontario) was added to each 
well with reincubation for another 30 min at room temperature. Then 
5 f.l1 of 0.4% trypan blue and 15 III of barbital buffer were added to each 
well for staining and fixation. The cell lysis ranged from 0 (undetecta-
ble) to 100%. The lymphocytotoxic antibody titer was defined as the 
highest serum dilution with more than 51 % cell lysis. Normal hamster 
serum served as a negative control. 
Indirect immunofluorescence: Snap-frozen normal hamster liver was 
the target tissue. It was cut into 2-1l sections, incubated with a protein 
blocking agent (Lipshaw, Pittsburgh, PAl, and then incubated again 
with sera obtained from normal LEW rats (to detect preformed anti-
bodies) or LEW recipients of hamster organs (to detect the antibody 
response). This was followed by goat antirat IgG or IgM to detect the 
localization, class, and intensity of the heterospecific antibodies. The 
location and intensity ofthe immunoglobulin deposits were determined 
without knowledge of the treatment regimen. 
Statistical analyses. The graft survival was so predictable in unmod-
ified rat recipients (3 days for hearts, 7 days for livers) that all survival 
extension beyond one day was statistically significant with the Mann-
Whitney U test. Median survival figures were calculated but survival 
of individual animals was given in all experimental groups. 
RESULTS 
Heart xenograft survival. Single drug therapy: When used as 
a single agent in a dose of 2 mg/kg/day, FK506 increased graft 
survival by only one day, significantly less prolongation than 
could be accomplished with BQR, RS-61443, cyclophospha-
mide, or methotrexate (Table 1). The therapeutic window of 
BQR was narrow, the drug being almost ineffective at 3 mg/ 
kg/day and clinically toxic if continued at 4.5 mg. The optimal 
dosing proved to be 4.0 mg/kg/day for 3 days and 3 mg/kg/day 
thereafter. The dose latitude with RS-61443 appeared to be 
somewhat greater (Table 1). 
Cyclophosphamide was the only drug that permitted consist-
ently successful heart transplantation. All of the animals given 
10 or 15 mg/kg/day cyclophosphamide are alive. Although 
follow-up is short because the experiments were done last, the 
superiority of cyclophosphamide to any other single agent was 
evident (Table 1). 
Combined therapy: Added to baseline therapy of 2 mg/kg/ 
day FK506 that was ineffectual alone, BQR and RS-61443 both 
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TABLE 1. Hamster heart graft survival in LEW rat recipients treated with FK506, BQR, RS-61443, cyclophosphamide, methotrexate, 
mizoribine, and deoxyspergualin as single agents" 
Group Agent Dose (mg/kg/ Duration Survival (days) Median survival day) (days) n (days) 
---
I 6 3, 3, 3, 3, 3, 3 3.0 
2 FK506 2.0 0-. 6 4,4,4,4,5,5 4.0 
3 BQR 3.0 -1-. 4 5,5,6,7 5.5 
4 BQR 4.0 X 3 -. 3.0 -1-> 6 5,8,8,11,12, >100 9.5 
5 BQR 4.5 -1-> 4 7,b 9,b >75, >75 >42.0 
6 RS-61443 20 -1-> 4 4,5,5,6 5.0 
7 RS-61443 40 -1-> 4 6,7,7,8 7.0 
8 RS-61443 60 X 3 -> 40 -1-> 6 6, 8,b 9, 9, 20, 23 9.0 
9 RS-61443 60 -1-> 4 9, 10, 13, 15 11.5 
10 Cyclophosphamide 7.5 -1-> 5 7, 8, 8, 8, 9 8.0 
11 Cyclophosphamide 10.0 -1-> 5 14, >15, >15, >15, >15 >15.0 
12 Cyclophosphamide 15.0 -1-> 5 >28, >28, >36, >36, >36 >36.0 
13 Methotrexate 0.5 -1-> 5 10, 11,b 13: 14,b > 16 13.0 
14 Mizoribine 7.5 -1-> 5 4,4,4,4,5 4.0 
15 DSPG 5.0 -1-> 3 4,4,4 4.0 
a BQR, RS-61443, Cyclophosphamide, Methotrexate, Mizoribine and Deoxyspergualin were administered from one day before transplantation 
and continued until graft rejection. 
b Animal died with functioning graft. 
permitted a spectacular improvement in heart xenograft sur-
vival. As when it was used alone, the BQR had a narrow 
therapeutic window with a single safe dose. The RS-61443 
could be used over a wide dose range in combination with 
FK506 with virtually 100% assurance of long survival (Table 
2, groups 7-10), whether it was given for 14 or 30 days. 
Duration of follow-up with most of the other antimetabolite 
drugs has been shorter. However, the early success rate with 
cyclophosphamide induction 7 to 30 days with doses of 7.5, 10, 
or 15 mg/kg/day appeared to be at least equivalent to RS-61443 
and BQR. Mizoribine was less effective and azathioprine had 
only a modest therapeutic effect when added in daily high doses 
to FK506, whereas mizoribine, methotrexate, and DSPG were 
of intermediate efficacy (Table 2). DSPG was the only drug 
tested as an adjuvant to FK506 that is not an antimetabolite. 
The animals given this drug developed alopecia and weight loss 
during its 30-day administration. 
Cyclophosphamide pretreatment: The 5 rats given a single 
dose of 80 mg/kg cyclophosphamide 10 days preoperatively and 
then treated with the usual daily regimen of FK506 after 
transplantation have all accepted their cardiac xenografts, with 
follow-ups of 2 months (Table 2, group 31). 
Liver xenograft survival. Single drug therapy: FK506 alone 
at 1 mg/kg/day increased survival 5-fold to 34.5 days, with 3 of 
10 animals surviving beyond 60 days and one beyond 100 days 
(Table 3); the results were similar to those reported earlier by 
Valdivia et a1. (17). BQR alone doubled median survival but 
only one of 7 animals lived beyond 19 days (Table 3). Results 
also were poor with RS-61443 and with the lowest dose of 7.5 
mg/kg/day cyclophosphamide. 
Combined therapy: When maintenance FK506 was combined 
with a 14-day course of 3 mg/kg/day BQR, the survival achiev-
able with either drug alone was remarkably enhanced (Table 
4) with 4 of 7 animals living for 100 days (group 1). Extending 
the daily BQR to 30 days (group 2) or giving it every other day 
from day 14 until 100 days (groups 3) caused a high delayed 
mortality. The animals appeared to have toxic reactions. 
RS-61443 with FK506 also greatly augmented survival when 
given for 14 days in the 2 relatively low doses of 20 and 30 mg/ 
kg, but the success rate was reduced, apparently because of 
toxicity, when the RS-61443 was continued for 30 days (Table 
4, group 5). 
Although the follow-up periods are shorter, the best results 
were with cyclophosphamide plus FK506 (Table 4, groups 8 
and 9). Virtually every animal had long survival-whether 
cyclophosphamide was given at the daily dose of 7.5 mg/kg, 
which was ineffective as monotherapy, or at the higher dose of 
10 mg. 
Splenectomy: The efficacy of FK506 also appeared to be 
improved with splenectomy (Table 4, group 7), a finding similar 
to that previously reported with hamster-to-rat heart xenotran-
splantation under monotherapy with FK506 (19) or with liver 
xenotransplantation under cyclosporine (16). 
Cyclophosphamide pretreatment: Nine of the 12 rats pre-
treated 10 days preoperatively with a single dose of 80 mg/kg 
cyclophosphamide have had long survival posttransplantation 
under FK506. 
Antibody correlation. Under FK506 as single-drug treatment 
for cardiac xenotransplantation, the heterospecific lymphocy-
totoxic antibodies that were present pretransplantation had 
astronomic increases by 3 or 4 postoperative days, coinciding 
with the humoral rejection of the hearts. Thirty-day induction 
therapy with BQR and RS-61443 partially prevented this (Fig. 
1). However, throughout the course until 100 days, low levels 
of xenospecific antibodies persisted without apparent harm 
(Fig. 1). 
The antibody titers after liver xenotransplantation under 
FK506 alone rose 10 times higher than after heart transplan-
tation alone, presumably because the livers survived long 
enough for the response to be complete (Fig. 2). The addition 
of BQR for a 14-day induction period blunted the antibody 
response more than RS-61443, but with both drugs the titer 
declined toward control levels after the 14-day course of the 
antiproliferative agents was stopped (Fig. 2). 
Humoral antibodies. Indirect immunofluorescence staining of 
heart and liver xenografts showed that the antibody was prin-
cipally IgM with light IgG deposition (Table 5). Liver recipients 
treated with FK506 only had considerable antibody concentra-
tion in vessels, but when antiproliferative drug treatment was 
added the staining was lighter and less blood-vessel-directed. 
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TABLE 2. Hamster heart graft survival in LEW recipients treated with combination treatment with FK506a 
Group Drug combined with Dose (mg/kg/ Duration Survival (days) Median survival FK506 day) (days) n (days) 
BQR 3.0 -1 --> 30 6 4,5,5,5,7, >100 5.0 
2 BQR 4.0 X 3 --> 3.0 -1 --> 13 5 >100, >100, >100, >100, >100 >100 
3 BQR 4.0 X 3 --> 3.0 -1--> 30 6 89, >100, >100, >100, >100, >100 >100 
4b BQR 4.0 X 3 --> 3.0 -1 --> 30 6 5,22,24, >100, >100, >100 >62.0 
5 BQR 4.5 -1--> 30 4 3,' 9,' >75, >75 >42.0 
6 RS-61443 10 -1 --> 30 6 4,5,5,5,>100,>100 5.0 
7 RS-61443 20 -1 --> 13 6 19, >78, >78, >78, >90, >90 >78.0 
8 RS-61443 20 -1 --> 30 6 >100, >100, >100, >100, >100, >100 >100.0 
9 RS-61443 30 -1 --> 30 6 >91, >91, >100, >100, >100, >100 >100.0 
10 vRS-61443 40 -1 --> 30 6 >78, >92,d >92,d >92, >100, >100 >92.0 
11 Cyclophosphamide 5 -1--> 30 5 5, 5, 5, 5, 6 5.0 
12 Cyclophosphamide 7.5 -1-->7 5 >35, >35, >35, >35, >35 >35.0 
13 Cyclophosphamide 7.5 -1 --> 13 5 >49,>49,>49,>50,>50 >49.0 
14 Cyclophosphamide 7.5 -1--> 30 5 >64,>64,>64,>64,>64 >64.0 
15 Cyclophosphamide 10 -1 --> 13 6 >50, >60, >63, >63, >64, >64 >63.0 
16 Cyclophosphamide 15 -1-->9 4 29, >43, >47, >47 >45.0 
17 Methotrexate 1.0 -1 --> 13 3 7,' 7,' 9' 7.0 
18 Methotrexate 1.0 -1-->5 3 9,' 10,' >40 10.0 
19 Methotrexate 1.0 -1-->3 7 8,10,10, >19, >19, >49, >49 >19.0 
20 Methotrexate 1.0 -1-->1 2 8, 9 8.5 
21 Methotrexate 0.5 -1-->9 4 10,' 13,' 43, >49 28.0 
22 Methotrexate 0.25 -1 --> 13 3 4,4,6 4.0 
23 Mizoribine 5.0 -1 --> 30 3 5,5,7 5.0 
24 Mizoribine 7.5 x 3 --> 5.0 -1 --> 30 6 3,' 5, 5, >77, >77, >100 >41.0 
25 Azathioprine 15 -1 --> 30 2 4, 5 4.5 
26 Azathioprine 45 -1 --> 30 3 5, 5, 23' 5.0 
27 Azathioprine 60 -1 --> 30 4 5, 8,' 17,' 19' 12.5 
28 DSPG 2.5 -1 --> 30 4 4, 5, 5, 5 5.0 
29 DSPG 5.0 x 3 --> 2.5 -1 --> 30 6 23, 38, >70, >70, >70, >76 >70.0 
30 DSPG 5.0 -1 --> 30 4 9, 24,' 32,' >76 28.0 
31 Cyclophosphamide 80.0 -10 5 >71, >71, >71, >79, >79 >71.0 
(i.p.) 
a FK506 was administered intramuscularly at a dose of 2.0 mg/kg/day for the first 6 days (days 0 to 5), then 1.0 mg/kg/day (days 6 to 30) and 
continued at 0.5 mg/kg/day every other day (days 31 to 100). 
b FK506 was used at 1.0 mg/kg/day for the first 30 days (0 to 30) and continued at 0.5 mg/kg/day every other day (days 31 to 100). 
, Animal died with functioning graft. 
d RS-61443 treatment was discontinued 25 days after transplantation because of the appearance of diarrhea and body weight loss. 
TABLE 3. Hamster liver graft survival in LEW rat recipients treated with FK506, BQR, RS-61443 and cyclophosphamide as single agents 
Dose (mg! Duration Median l-month lOO-day Group Agent kg/day) (days) n Survival (days) survival survival survival (days) rate (%) rate (%) 
1 8 6,7,7, 7, 7, 7, 7, 8 7.0 0 0 
2 FK506 1.0 0-30" 10 7,11,18,19,21,48, 34.5 50 10 
58,72,94, >100 
(5/10) (1/10) 
3 BQR 3.0 O-Death 7 7,8,9,12,17,19,74 12.0 14.3 0 
(1/7) 
4 RS-61443 20.0 O-Death 5 7,7,7, 7,8 7.0 0 0 
5 Cyclophosphamide 7.5 O-Death 5 7, 7, 9, 9, 9 9.0 0 0 
a FK506 was used at a dose of 1.0 mg/kg/day for the first 30 days (0 to 30) and continued at 0.5 mg/kg/day every other day (days 31 to 100). 
DISCUSSION 
The moderately difficult hamster-to-rat model of xeno-
transplantation has been investigated extensively by Valdivia 
and Monden (14-17) and by others, including Knechtle et a1. 
(20), who reported the mean survival of heterotopic hearts for 
>100 days with total-lymphoid irradiation plus cyclosporine. 
This accomplishment could not be duplicated by later workers 
(21, 22). Marchman et a1. (23) reported that TLI plus DSPG 
increased heart xenograft survival to a mean of 26 days. By 
inhibiting complement fixation with snake venom in cyclo-
sporine-treated rats, Van Den Bogaerde et a1. (24) were able to 
increase heart graft survival to a mean of 50 days, with 2 of 10 
animals living for 100 days. These last investigators emphasized 
the duality of the humoral and cellular mechanisms of xenograft 
rejection. 
The special value of the hamster-to-rat xenograft models for 
the screening of immunosuppressive drug combinations was 
evident from our experiments. A hamster organ is confronted 
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TABLE 4. Hamster liver graft survival in LEW rat recipients treated with combination treatment with FK506a 
Dose (mg/ Duration Median survival l·month Group Agent kg/day) (days) n Survival (days) (days) survival (%) 
1 BQR 3.0 0-13 7 21,42,81, >100, >100, >100, >100 >100 85.7 
(6/7) 
2 BQR 3.0 0-30 7 13,21,23,32,36,46, >100 32.0 57.1 
(4/7) 
3 BQR 3.0 0-13" 9 15, 15, 19, 30, 38, > 100, > 100, > 100, 38.0 66.7 
>100 
(6/9) 
4 RS 61443 20 0-13 10 25,83, >100, >100, >100, >100, >100.0 90.0 
>100,>100,>100,>100 
(9/10) 
5 RS 61443 20 0-30 9 12,22,30,36,54, >100, >100, >100, 54.0 77.8 
>100 
(7/9) 
6 RS 61443 30 0-13 10 15,15,39,76, >82, >84, >96, >97, >83.0 80.0 
>97, >98 
(8/10) 
7 Splenectomy 6 9,11,18,61, >100, >100 39.5 50.0 
(3/6) 
8 Cyclophosphamide 7.5 M~9 10 10,31, >40, >45, >45, >45, >47, >48, >45.0 90.0 
>48, >51 
(9/10) 
9 Cyclophosphamide 10.0 M~9 5 >32, >32, >32, >39, >39 >32.0 100.0 
(5/5) 
10 Cyclophosphamide 80.0 -10 12 12, 13,20, >46, >47, >47, >47, >47, >47.0 75.0 
>65, >66, >66, >66 
(i.p.) (once) (9/12) 
a FK506 was used at 1.0 mg/kg/day for the first 30 days (0 to 30) and continued at 0.5 mg/kg/day every other day (days 31 to 100). 
b BQR was administered for the first 14 days and continued on alternate days from days 14 to 100 at a dose of 3.0 mg/kg/day. 
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FIGURE 1. Antihamster lymphocytotoxic antibody after heart trans· 
plantation. 
in the rat by a moderate titer (1:16-1:32) of preformed heter-
ospecific cytotoxic antibodies, and subsequently by a rapidly 
gathering antibody storm that destroys cardiac grafts within 3 
days in untreated recipients, before there is a trace histopath-
ologically of immunocyte infiltration. The liver, which is more 
resistant to antibody-mediated injury (17, 25, 26), survives this 
initial onslaught but cellular rejection becomes increasingly 
evident beyond 3 days until death of the unmodified host after 
7 days from combined humoral and cellular rejection. Thus the 
use of these 2 organs for testing allows at the outset a stratifi· 
cation in untreated animals of the 2 distinctive mechanisms of 
FIGURE 2. Antihamster lymphocytotoxic antibody response after 
liver transplantation. Note that the log 2 scale is X10, to accommodate 
the far greater rise in titer compared with that in heart recipients (see 
Fig. 1). 
humoral and cellular graft rejection, and makes it clear that 
the mitigation or interdiction of either alone will not consist-
ently permit long-term graft survival. 
This generalization was verified with testing of all of the 
individual drugs that contributed to our most effective cock-
tails. Although FK506 and the antiproliferative drugs used most 
extensively (RS-61443 and BQR) significantly improved heart 
and liver xenograft survival when used alone, they did not 
permit consistent long-term survival. Survival became rou-
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TABLE 5. Hepatic specificity of xenoantibodies in sera of liver recipients by indirect immunofluorescence" 
----------
7-8 Days after transplantation 30-40 Days after transplantation 
Treatment 
FK506 1.0 mg/kg 
FK506 1.0 mg/kg + RS-61443 20 mg/kg 
(0-13) 
FK506 1.0 mg/kg + BQR 3.0 mg/kg (0-
13) 
Sinusoids 
+++ 
++ 
++ 
++ 
+ 
+ 
-----------------, -- ~---~ -
Large vessel 
endothelium 
+++ 
++ 
++ 
++ 
+ 
+ 
Sinuosids Large vessel 
endothelium 
,---------
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
± 
• Immunofluorescent intensity was scored on a qualitative scale from 0 to 3+; values were shown as IgM deposits. 
tinely possible when continuous FK506 was combined with a 
shout course of BQR, which inhibits de novo pyrimidine syn-
thesis by blocking the enzyme dihydroorotate dehydrogenase 
(27), or of RS-61443, which (like mizoribine) inhibits de novo 
purine synthesis by blocking enzyme inosine monophosphate 
dehydrogenase (28). 
Although less-extensive data were acquired with mizoribine 
and azathioprine, these antiproliferative agents appeared less 
capable of augmenting FK506 efficiency. In contrast, cyclo-
phosphamide, another purine antimetabolite with considerable 
B cell specificity (29) was unexpectedly effective as monoth-
erapy in prolonging heart xenograft survival and in allowing 
the routine acceptance of heart xenografts in FK506-treated 
recipients when the cyclophosphamide was given as a single 
large dose 10 days before transplantation or in a 9-day course 
postoperatively in smaller doses. The ability to effectively use 
cyclophosphamide for daily dosing in the xenograft model has 
direct clinical implications for clinical xenograft trials because 
this drug has been shown in extensive clinical trials of renal 
and liver transplantation to be as safe and effective as azathi-
oprine when used as the baseline drug for chronic therapy (30-
32). Azathioprine had low efficacy in the hamster-to-rat heart 
model, and methotrexate and mizoribine were in between. 
DSPG, the synthetically hydroxylated fermentation product 
of Bacillus lactobacillus, the mechanism of action of which is 
not as well understood, appeared capable of filling the same 
handmaiden role to FK506 as the antimetabolite drugs, but the 
animals lost weight, developed alopecia, and appeared system-
ically toxic when effective doses were used. DSPG has been 
described as ameliorating preformed antibody states, including 
those in xenotransplantation (13, 23). 
After orthotopic hepatic xenotransplantation, the perioper~ 
ative survival of the liver with its well-known resistance to 
antibodies was less dependent than the heart on the antime-
tabolite component of the combined drug therapy-and, in 
contrast to the heart xenograft experiments, cyclophosphamide 
as monotherapy had little value for hamster-to-rat liver xeno-
transplantation-seemingly less than BQR or RS-61443. How-
ever, when any of these 3 agents was used in a brief induction 
course for continuous treatment with FK506, the results were 
converted from unpredictable and unacceptable to almost in-
variably successful. 
Thus, by breaking down the antibody barrier to xeno-
transplantation with several of these so-called antiproliferative 
drugs as well as with DSPG, it has been possible with FK506 
to transplant hearts and livers in the moderately difficult 
hamster-to-rat xenotransplantation model as easily as in most 
allogeneic strain combinations and more easily than in some. 
The therapeutic benefit of the adjuvant agents correlated with 
the ability of the adjuvant drug to inhibit the antihamster 
antibody response peri operatively, although this correlation 
was imprecise later in the course, the reappearance of the 
antibodies was not predictably harmful. Once the first 2 weeks 
were past, treatment with antiproliferative agents was no longer 
necessary-and, in fact, its continuation may have been a 
liability in that some of the rats appeared ill unless these agents 
were stopped. The minor benefit of splenectomy in one of our 
liver subgroups was thought to be by abridging the humoral 
immune response. The imperfect correlation between the 
suppression of generic heterospecific antibodies by these drugs 
and the clinical results, particularly with cyclophosphamide, 
has been explained by further studies (manuscript in prepara-
tion) showing that xenograft rejection is dependent on an IgM-
producing subpopulation of splenic B cells and NK cells. 
Thus, we are reporting here the conclusion that interdiction 
of the B cell proliferative response holds the key to the critical 
first step of xenotransplantation. This concept should be clin-
ically relevant, provided that the humoral antibody reaction is 
not so instantaneous that it causes hyperacute rejection in a 
matter of a few minutes or hours. It is known from experience 
that baboon-to-human xenotransplantation fulfils this condi-
tion (33, 34). The prime candidate drug to prevent the heter-
ospecific humoral rejection response is cyclophosphamide, al-
though the experimental drugs RS-61443 and BQR are prom-
ising. 
Once the antibody barrier is breached, the need for the 
antiproliferative drugs apparently diminishes, as was shown by 
the ability to routinely stop cyclophosphamide, RS-61443, and 
BQR in 2 weeks or less without subsequent humoral rejection 
in spite of the continued presence or in some animals a delayed 
rise of the antihamster antibodies. In the hamster-to-rat model, 
monotherapy with FK506 was all that was required from 2 
weeks onward. It was shown previously that with stoppage of 
FK506 at 100 days, the hamster heart or liver xenograft is 
rejected, primarily by cellular mechanisms, after several weeks 
to months (19). 
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DISCUSSION 
DR. AUCHINCLOSS (Boston, Massachusetts): Do you 
think the two drugs are prolonging survival more effectively 
than one alone because they're acting synergistically on a single 
mechanism of rejection, or are they working on two different 
mechanisms of rejection? 
One way of examining that question would be to test the two 
drugs together in allograft combinations. Do you see the same 
synergistic effect when using an allograft? 
DR. MURASE: In the allograft system we have a different 
experiment because we use a very low dose of FK506. With 
antiproliferative drugs at these low doses, an additive or syn-
ergistic effect is observed on allograft survival. 
DR. AUCHINCLOSS: I'm sorry, you do see synergistic ef-
fect? 
DR. MURASE: Yes. 
DR. SOLLINGER (Madison, Wisconsin): This is the longest 
graft survival ever reported using drug therapy in this xenograft 
model. 
I have two questions. What did the histology show in your 
cardiac model? How about FK506 plus Brequinar versus FK506 
and RS61443? I am particularly interested in the histology of 
the coronary arteries. 
The second question is if you would have a choice clinically 
to use either RS61443 or Brequinar in conjunction with FK506, 
what would you recommend? 
---------
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DR. MURASE: We have histology for the greater than 100 
day survivors. This was reviewed by Dr. Jake Demetris, who 
found no coronary artery changes. 
Perhaps Dr. Starzl should answer the second question. 
DR. STARZL (Pittsburgh, Pennsylvania): I think that any 
of the drugs you mentioned would be fine. My impression is 
that there is a wider margin of acceptable drug dose with the 
RS61443 than with Brequinar, which really has to be used right 
at the 3.5 to 4 mg/kg range. Whereas with RS61443, one can 
see an effective dose range all the way from just above 10 mg/ 
kg up to 60 mg/kg. 
However, I think it's worth pointing out that Cytoxan does 
the same thing. Although less efficient, methotrexate seems 
similar. The important point is that Dr. Murase has exposed a 
generic discovery, not an advocacy of a particular drug. Thus, 
several of the antimetabolites can be used as an adjuvant to 
"jump-start" maintenance treatment with FK506. Because of 
anxiety on the part of the drug companies about using experi-
mental drugs together, it seems likely that a drug like Cytoxan 
will be used first with FK506 if clinical trials are attempted. 
DR. AUCHINCLOSS: Dr. Starzl, you're the only person who 
has put an animal liver into a human being. With these new 
drugs now becoming available, are you prepared to do that 
again? 
DR. STARZL: That's a policy decision that I wouldn't care 
to make myself. It involves the institutional IRBs and it in-
volves the FDA and the NIH. There would have to be a 
substantial consensus before anyone would want to attempt 
such a trial. I have the impression, because of the delicate 
nature of the undertaking, that there will only be one or two 
opportunities to do it, so it's rather important that it succeed. 
However, the basic tools to make it succeed are within our 
hands. In 1963, we transplanted six baboon-to-human kidney 
heterografts. None hyperacutely rejected. They all functioned 
for more than six days, to a maximum of 60 days. All grafts 
were eventually lost because of the syndrome that Dr. Murase 
has been able to interdict, that is, the delayed humoral rejection. 
I don't know of any undertaking in clinical transplantation 
that is more thoroughly supported than a potential trial of 
xenotransplantation. With Dr. Murase's model, which is a very 
difficult one, she has been consistently able to get better results 
than most people 6 to 12 months ago could do with a whole 
variety of fairly difficult allograft models. It is a stunning set 
of data; except for the FK506, the achievement is not particu-
larly drug specific. 
It's like getting to a precious jewel encased in an impermeable 
shell. She has broken the shell with the antiproliferative drugs. 
It's quite an amazing story. 
DR. AUCHINCLOSS: I agree entirely. 
DR. STARZL: Can I just add one thing, because I think Dr. 
Murase said this in a way that might be misunderstood. At 100 
days, the pathology in most of these hearts was absolutely 
normal. That is, when specimens were presented to Dr. De-
metris as unknowns, he had trouble determining which was the 
xenograft heart and which was the native heart. 
DR. BACH (New York, New York): Could you explain what 
you meant when you say that the heart is simply a vascular 
form of rejection, whereas the liver is the combination of 
vascular and cellular? I ask this especially when you show us 
that at least by the assay you used for natural antibodies, that 
they go up very much with the combined treatment of FK506, 
and either Brequinar or RS61443. Yet you get survival despite 
that. 
DR. STARZL: The phenomenon is, of course, one which you 
have given the name "accommodation." When you and I last 
discussed this, it was in terms of transfection of human genes 
into xenograft endothelium. If you can succeed for a while, and 
it looks as if the magic time is 13 or 14 days, the continuing 
presence of these preformed antibodies may no do harm. This 
would not be without precedent, since it has been observed in 
recipients of allografts who "ride out" preformed cytotoxic 
antibodies. 
But I'm only expressing my own particular brand of wonder-
ment about the fact that enormous delayed rises in titer don't 
kill the graft. 
The differentiation, between humoral and cellular rejection 
is made possible with 2 different kinds of organ grafts. On one 
hand, the heart xenograft at three days in untreated rats, or at 
four days in rats treated with FK506-with no histopathologic 
evidence of cellular rejection. Also, the liver, known to be 
relatively resistant to humoral rejection, survives long enough 
to identify a cell mediated component along with the charac-
teristic changes of humoral rejection in the blood vessels. The 
cellular component by this time is very aggressive. This com-
bination lesion is not unfamiliar. We have often seen it in 
allografts. 
DR. BACH: That is precisely why I asked the question. It 
seems that is not induction of accommodation, it is accommo-
dation! 
My concern, is that we don't know as much about a combi-
nation, such as hamster-to-rat, as we do, for instance about 
pig-to-nonhuman primate. As such, I'm not quite sure how to 
think about antibody, complement, or other factors in the 
vascular rejection. 
DR. STARZL: Thank you for putting the question that way. 
We think the barriers are the same; they differ only quantita-
tively. At a practical level, what is required to win in a human 
situation is to pick a species combination where you do not get 
hyperacute rejection within minutes before you can do some-
thing to break through the antibody barrier. With hyperacute 
rejection, the game is over. 
By empirical experience, there are at least 3 animal-human 
combinations that qualify: the baboon-to-human (the kidney 
experience of 1963 and the Baby Faye case of 1984), the 
chimpanzee to human experience of Reemtsma, and the Rhesus 
monkey experience of Reemtsma. The Rhesus monkey was the 
least satisfactory because it was fiercely rejected after about 
three days, but hyperacute rejection did not occur. The best 
donor, the chimpanzee, cannot be used again because this is an 
endangered species. This appears to leave us with the baboon. 
The work being done at Duke and at your place looking at 
in vitro antibody reactivities may well be predictive of other 
interspecies possibilities, but right now it seems to me that the 
pig-to-human is too tough. 
More than 25 years ago, Rene Kuss of Paris tried a pig-to-
human kidney xenotransplant, under Imuran and prednisone, 
at a time when dialysis was not available. Kuss has described 
to me in detail how the kidney was hyperacutely rejected in 
about 15 minutes. Thus the pig cannot qualify unless, or until, 
we can do something to move that antibody barrier back. 
